Blood Pressure-Lowering Device to be Available at 1,440 Stores in May 2008
NEW YORK and LONDON, April 28 /PRNewswire/ -- InterCure Ltd., a medical device company publicly traded on the Tel Aviv Stock Exchange (TASE: INCR), today announced that its RESPeRATE(R) hypertension treatment device, clinically-proven to significantly lower blood pressure, will launch into full-scale retail distribution within the United Kingdom this May through Lloyds Pharmacy, the leading community pharmacy chain in the UK.
Per the distribution agreement, Lloyds Pharmacy will distribute RESPeRATE in 1,440 stores beginning in May 2008 and for a limited period will be the only nation-wide UK retail chain to carry the product. As part of the launch, RESPeRATE, retailing at 199 pounds Sterling, will be prominently displayed as part of Lloyds in store merchandising programmes. This prime position will allow consumers to learn more about RESPeRATE and interact with the device. Lloyds Pharmacy will also offer product demonstrations to instruct consumers how to successfully include RESPeRATE into their overall hypertension management regimen.
"With many of our shoppers looking for new ways to manage hypertension with a treatment that fits into their lifestyles, we are pleased to offer RESPeRATE as a complement to our existing line of innovative healthcare products and services," said Justin Woodward, senior marketing manager at Lloyds Pharmacy.
"The full-chain launch of RESPeRATE at Lloyds Pharmacy clearly demonstrates the broad appeal of our effective and truly natural device-guided breathing therapy for hypertension," said Erez Gavish, president and CEO of InterCure. "Commanding a premium 199 pounds price point at this respected retailer is yet another validation of the value of RESPeRATE in the management of high blood pressure. Lloyds Pharmacy has built a strong reputation by educating consumers and providing them with innovative healthcare products that meet their medical needs. RESPeRATE is a perfect fit for Lloyds Pharmacy customers looking to take control of their hypertension with the help of their trusted community pharmacy."
Sixteen million adults in the UK suffer from high blood pressure. Left untreated, it may lead to heart attack, stroke and kidney or heart failure.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books including Mayo Clinic's On High Blood Pressure and the American Heart Association's Hypertension Primer.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
About Lloyds Pharmacy
Lloyds Pharmacy has 1,700 pharmacies across the country. These are based predominantly in community and health centre locations. The company employs over 16,000 staff, of which 80 percent are women, and dispenses 120 million prescription items annually. The pharmacies have over two million visits per week by customers who are also predominantly women.
Lloyds Pharmacy is the trading name of Lloyds Pharmacy Ltd, a wholly owned subsidiary of Celesio AG based in Stuttgart. Celesio is the leading pharmaceutical distribution company in Europe and is represented in 15 countries. With its three divisions, Celesio Wholesale, Celesio Pharmacies and Celesio Solutions, the group covers the entire scope of pharmaceutical trade and pharmaceutical-related services. Lloyds Pharmacy which is a community pharmacy has primary care at the heart of its business. This is why it has launched a range of products aimed at community health such as affordable blood pressure monitors, Solar Safe products and is a supporter of NHS initiatives such as NHS Choices by providing terminals in-store for patient information.
This news release may contain forward-looking statements that are based
on the Company's current beliefs and assumptions and on information
currently available to its management. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
Company's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements. As a result of these risks,
uncertainties and other factors, readers are cautioned not to place undue
reliance on any forward-looking statements included in this press release.
These forward- looking statements represent beliefs and assumptions only as
of the date of this news release, and the Company assumes no obligation to
update these forward-looking statements publicly, even if new information
becomes available in the future.
Amanda Lazaro Brian Packard
Schwartz Communications InterCure, Inc.
+1-781-684-0770 +1-646-652-5800 x.7134
|SOURCE InterCure Ltd.|
Copyright©2008 PR Newswire.
All rights reserved